logo

Albireo Pharma, Inc. (ALBO)



Trade ALBO now with
  Date
  Headline
9/8/2021 8:38:05 AM Albireo Pharma: MHRA Grants Marketing Authorization For Bylvay For Progressive Familial Intrahepatic Cholestasis
9/8/2020 6:44:06 AM Albireo Pharma Announces Positive Topline Results From PEDFIC 1 Trial
9/7/2020 10:14:16 PM Albireo To Announce Results From PEDFIC 1 Phase 3 Trial Of Odevixibat On September 8
7/14/2020 7:38:58 AM Albireo Pharma Enrolls First Patient In Phase 3 Clinical Trial Of Odevixibat In Biliary Atresia
3/10/2020 8:36:01 AM Albireo Completes Enrollment In Phase 2 Study Of Elobixibat In NASH/NAFLD
8/9/2019 8:02:49 AM Wedbush Is Lowering Albireo Pharma, Inc. (ALBO) FY20 Estimate To -5.48 From -5.41
8/9/2019 8:02:37 AM Wedbush Is Cutting Albireo Pharma, Inc. (ALBO) Q4 20 Estimate To -1.36 From -1.34
8/9/2019 8:02:23 AM Wedbush Is Cutting Albireo Pharma, Inc. (ALBO) Q3 20 Estimate To -1.36 From -1.34
8/9/2019 8:02:06 AM Wedbush Is Cutting Albireo Pharma, Inc. (ALBO) Q2 20 Estimate To -1.37 From -1.36
8/9/2019 8:01:53 AM Wedbush Is Lowering Albireo Pharma, Inc. (ALBO) Q1 20 Estimate To -1.38 From -1.37
8/9/2019 8:01:37 AM Wedbush Is Raising Albireo Pharma, Inc. (ALBO) FY19 Estimate To -5.43 From -5.54
8/9/2019 8:01:25 AM Wedbush Is Raising Albireo Pharma, Inc. (ALBO) Q4 19 Estimate To -1.35 From -1.37
8/9/2019 8:01:14 AM Wedbush Is Increasing Albireo Pharma, Inc. (ALBO) Q3 19 Estimate To -1.35 From -1.36
8/9/2019 8:00:21 AM Wedbush Reiterates Albireo Pharma, Inc. (ALBO) At Outperform With $69 Price Target